Drug Profile
Azilsartan medoxomil/chlortalidone - Takeda
Alternative Names: Azilsartan kamedoxomil/chlortalidone; Chlortalidone/azilisartan medoxomil; EdarbiClo; Edarbyclor; Edarclor; TAK-491/chlorthalidone; TAK-491CLDLatest Information Update: 24 Feb 2021
Price :
$50
*
At a glance
- Originator Takeda
- Developer Synokem Pharmaceuticals; Takeda
- Class Antihypertensives; Benzimidazoles; Small molecules; Sulfonamides
- Mechanism of Action Angiotensin receptor antagonists; Thiazide-like diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 24 Feb 2021 No development reported - Phase-III for Hypertension in India (PO)
- 01 Jul 2020 Launched for Hypertension in Portugal (PO)
- 11 Dec 2019 Launched for Hypertension in Ukraine (PO)